Compare Stocks: ABCL, HALO, BBIO, and SMMT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$11.82 +4.0%	$12.16	$2.74 ▼ $15.02	$3.62B	1.41	5.28 million shs	3.02 million shs
BBIO BridgeBio Pharma	$68.56 +0.6%	$71.28	$54.23 ▼ $93.42	$13.40B	0.97	2.68 million shs	2.40 million shs
HALO Halozyme Therapeutics	$125.63 +0.9%	$111.37	$61.22 ▼ $126.23	$14.14B	0.88	2.41 million shs	1.53 million shs
SMMT Summit Therapeutics	$15.47 -0.5%	$15.87	$12.07 ▼ $29.23	$12.44B	-1.51	7.09 million shs	3.21 million shs

The 7 Best High-Yield Dividend Stocks for 2027

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	+3.96%	+0.17%	-3.98%	+122.60%	+116.09%
BBIO BridgeBio Pharma	+0.65%	+3.27%	+4.34%	-18.40%	+28.78%
HALO Halozyme Therapeutics	+0.88%	+3.11%	+11.73%	+53.34%	+91.01%
SMMT Summit Therapeutics	-0.51%	+5.74%	-5.96%	+13.25%	-19.26%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$11.82 +4.0%	$12.16	$2.74 ▼ $15.02	$3.62B	1.41	5.28 million shs	3.02 million shs
BBIO BridgeBio Pharma	$68.56 +0.6%	$71.28	$54.23 ▼ $93.42	$13.40B	0.97	2.68 million shs	2.40 million shs
HALO Halozyme Therapeutics	$125.63 +0.9%	$111.37	$61.22 ▼ $126.23	$14.14B	0.88	2.41 million shs	1.53 million shs
SMMT Summit Therapeutics	$15.47 -0.5%	$15.87	$12.07 ▼ $29.23	$12.44B	-1.51	7.09 million shs	3.21 million shs

The 7 Best High-Yield Dividend Stocks for 2027

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	+3.96%	+0.17%	-3.98%	+122.60%	+116.09%
BBIO BridgeBio Pharma	+0.65%	+3.27%	+4.34%	-18.40%	+28.78%
HALO Halozyme Therapeutics	+0.88%	+3.11%	+11.73%	+53.34%	+91.01%
SMMT Summit Therapeutics	-0.51%	+5.74%	-5.96%	+13.25%	-19.26%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABCL AbCellera Biologics	2.80	Moderate Buy	$13.89	17.50% Upside
BBIO BridgeBio Pharma	2.88	Moderate Buy	$104.40	52.28% Upside
HALO Halozyme Therapeutics	2.77	Moderate Buy	$99.55	-20.76% Downside
SMMT Summit Therapeutics	2.58	Moderate Buy	$28.61	84.92% Upside

Current Analyst Ratings Breakdown

Latest ABCL, HALO, BBIO, and SMMT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/21/2026	BBIO BridgeBio Pharma	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Overweight	$97.00 ➝ $87.00
10/19/2026	BBIO BridgeBio Pharma	Piper Sandler Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$115.00 ➝ $120.00
10/19/2026	BBIO BridgeBio Pharma	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Neutral	$94.00 ➝ $91.00
10/16/2026	HALO Halozyme Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$130.00
10/15/2026	ABCL AbCellera Biologics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	SMMT Summit Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/15/2026	BBIO BridgeBio Pharma	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$82.00 ➝ $92.00
10/14/2026	BBIO BridgeBio Pharma	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
10/13/2026	HALO Halozyme Therapeutics	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold ➝ Strong-Buy
10/13/2026	HALO Halozyme Therapeutics	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$105.00 ➝ $130.00

(Data available from 10/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABCL AbCellera Biologics	$75.13M	48.24	N/A	N/A	$3.23 per share	3.66
BBIO BridgeBio Pharma	$502.08M	26.69	N/A	N/A	($10.77) per share	-6.37
HALO Halozyme Therapeutics	$1.40B	10.21	$4.81 per share	26.10	$0.42 per share	299.12
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	$0.85 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABCL AbCellera Biologics	-$146.41M	-$0.54	N/A	N/A	N/A	-248.83%	-17.49%	-12.36%	11/9/2026 (Confirmed)
BBIO BridgeBio Pharma	-$724.93M	-$3.57	N/A	N/A	N/A	-97.03%	N/A	-61.19%	10/29/2026 (Estimated)
HALO Halozyme Therapeutics	$316.89M	$3.35	37.50	12.83	0.47	24.86%	260.98%	23.91%	11/5/2026 (Estimated)
SMMT Summit Therapeutics	-$1.08B	-$1.12	N/A	N/A	N/A	N/A	-168.94%	-141.92%	10/26/2026 (Estimated)

Latest ABCL, HALO, BBIO, and SMMT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	SMMT Summit Therapeutics	-$0.2806	N/A	N/A	N/A	$0.07 million	N/A
11/9/2026	Q3 2026	ABCL AbCellera Biologics	-$0.1757	N/A	N/A	N/A	$6.25 million	N/A
11/5/2026	Q3 2026	HALO Halozyme Therapeutics	$2.30	N/A	N/A	N/A	$490.85 million	N/A
10/29/2026	Q3 2026	BBIO BridgeBio Pharma	-$0.5389	N/A	N/A	N/A	$293.48 million	N/A
10/26/2026	Q3 2026	SMMT Summit Therapeutics	-$0.2806	N/A	N/A	N/A	$0.07 million	N/A
8/10/2026	Q2 2026	BBIO BridgeBio Pharma	-$0.5756	-$0.78	-$0.2044	-$0.78	$220.91 million	$243.68 million
8/6/2026	Q2 2026	HALO Halozyme Therapeutics	$1.79	$2.28	+$0.49	$1.90	$402.28 million	$481.00 million
8/5/2026	Q2 2026	ABCL AbCellera Biologics	-$0.1640	-$0.18	-$0.0160	-$0.18	$7.85 million	$4.05 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABCL AbCellera Biologics	N/A	N/A	N/A	N/A	N/A
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
HALO Halozyme Therapeutics	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABCL AbCellera Biologics	N/A	12.77	12.77
BBIO BridgeBio Pharma	N/A	1.23	1.17
HALO Halozyme Therapeutics	13.50	2.71	2.31
SMMT Summit Therapeutics	N/A	6.96	6.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABCL AbCellera Biologics	61.42%
BBIO BridgeBio Pharma	99.85%
HALO Halozyme Therapeutics	97.79%
SMMT Summit Therapeutics	4.61%

Insider Ownership

Company	Insider Ownership
ABCL AbCellera Biologics	28.40%
BBIO BridgeBio Pharma	14.23%
HALO Halozyme Therapeutics	2.50%
SMMT Summit Therapeutics	83.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABCL AbCellera Biologics	562	306.61 million	219.53 million	Optionable
BBIO BridgeBio Pharma	839	195.49 million	167.67 million	Optionable
HALO Halozyme Therapeutics	423	113.50 million	110.66 million	Optionable
SMMT Summit Therapeutics	265	799.73 million	131.96 million	Optionable

ABCL, HALO, BBIO, and SMMT Headlines

Recent News About These Companies

Summit Therapeutics and Lunit partner on AI pathology for cancer research

October 24 at 1:11 AM | streetinsider.com

Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development

October 23 at 9:26 PM | prnewswire.com

Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development

October 23 at 4:37 PM | businesswire.com

Summit Expands Ivonescimab Development Into Biliary Tract Cancer

October 22 at 11:50 AM | zacks.com

Summit Therapeutics PLC (NASDAQ:SMMT) Stock Rated "Moderate Buy" by Wall Street Brokerages

October 22 at 1:59 AM | americanbankingnews.com

Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary ...

October 21 at 12:08 PM | manilatimes.netM

Summit Therapeutics and ECOG-ACRIN to trial ivonescimab in bile duct cancer

October 21 at 12:08 PM | streetinsider.com

Can Expanding Ivonescimab Development Unlock SMMT's Growth Potential?

October 21 at 12:01 PM | zacks.com

Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer

October 21 at 8:42 AM | prnewswire.com

Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer

October 21 at 6:05 AM | businesswire.com

Summit Therapeutics Stock Rises 7% Over Initiation Of Global Phase II Study Of Ivonescimab

October 19, 2026 | rttnews.com

Summit Therapeutics (NASDAQ:SMMT) Shares Up 6.1% - Still a Buy?

October 19, 2026 | marketbeat.com

Summit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell Carcinoma

October 19, 2026 | finance.yahoo.com

Summit Therapeutics PLC (NASDAQ:SMMT) Stock Has Average Price Target of $28.61

October 17, 2026 | marketbeat.com

Summit Therapeutics Sees Unusually Large Options Volume (NASDAQ:SMMT)

October 13, 2026 | marketbeat.com

Summit Therapeutics (NASDAQ:SMMT) Shares Down 5.8% - Here's What Happened

October 13, 2026 | marketbeat.com

Summit Therapeutics (SMMT) Set to Release Quarterly Earnings on Monday

October 12, 2026 | marketbeat.com

Summit Therapeutics (NASDAQ:SMMT) Stock Jumps 3.6% - What's Next?

October 7, 2026 | marketbeat.com

SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway Combos

October 5, 2026 | zacks.com

Summit Therapeutics (SMMT) Is Up 7.3% After $2 Billion AstraZeneca Partnership and Trial Collaboration

October 2, 2026 | finance.yahoo.com

Daiichi Sankyo, AstraZenca, Summit Partner To Evaluate Datroway Plus Ivonescimab

October 2, 2026 | rttnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ABCL, HALO, BBIO, and SMMT Company Descriptions

AbCellera Biologics NASDAQ:ABCL

$11.82 +0.45 (+3.96%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$11.78 -0.04 (-0.34%)

As of 10/23/2026 07:58 PM Eastern

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

BridgeBio Pharma NASDAQ:BBIO

$68.56 +0.44 (+0.65%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$68.57 +0.01 (+0.01%)

As of 10/23/2026 07:56 PM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Halozyme Therapeutics NASDAQ:HALO

$125.63 +1.09 (+0.88%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$125.64 +0.01 (+0.01%)

As of 10/23/2026 07:30 PM Eastern

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Summit Therapeutics NASDAQ:SMMT

$15.47 -0.08 (-0.51%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$15.48 +0.01 (+0.06%)

As of 10/23/2026 07:59 PM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ABCL, HALO, BBIO, and SMMT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ABCL, HALO, BBIO, and SMMT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ABCL, HALO, BBIO, and SMMT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ABCL, HALO, BBIO, and SMMT Company Descriptions

AbCellera Biologics NASDAQ:ABCL

BridgeBio Pharma NASDAQ:BBIO

Halozyme Therapeutics NASDAQ:HALO

Summit Therapeutics NASDAQ:SMMT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ABCL, HALO, BBIO, and SMMT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ABCL, HALO, BBIO, and SMMT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ABCL, HALO, BBIO, and SMMT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ABCL, HALO, BBIO, and SMMT Company Descriptions

AbCellera Biologics NASDAQ:ABCL

BridgeBio Pharma NASDAQ:BBIO

Halozyme Therapeutics NASDAQ:HALO

Summit Therapeutics NASDAQ:SMMT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools